Drug Price Debate May Not Hinder Biotech ETFs After All

September 20, 2021

The issue of pharmaceuticals pricing reform — a long-time favorite discussion on Capitol Hill — is gaining momentum, and some healthcare assets are bearing that burden. For example, the ALPS Medical Breakthroughs ETF (SBIO) is lower by 2.35% over the past week as investors fret about the specter of price regulations in the biotech space, which are seen as a roadblock to research and development efforts.

Read the source article at ETF Trends
2021-09-16 14:59:35

Share This Story!